News | Heart Valve Technology | May 11, 2018

First-Ever Risk Tool Helps Predict TAVR Readmission Rates

New tool shows potential to identify patients at higher risk for readmissions, target post discharge interventional strategies and reduce incidence of readmissions for TAVR patients

First-Ever Risk Tool Helps Predict TAVR Readmission Rates in 2018 SCAI late-breaking study. #SCAI, #SCAI2018

May 11, 2018 — A new study looked at the effectiveness of a novel risk tool to predict 30-day readmission rates in patients undergoing transcatheter aortic valve replacement (TAVR). This first-ever tool calculates a score to help clinicians and medical professionals predict risk of 30-day readmission for TAVR patients and can be easily incorporated in patient electronic medical records (EMR). The study was presented at the Society for Cardiovascular Angiography and Interventions (SCAI) 2018 Scientific Sessions, April 25-28 in San Diego.

More than 5 million Americans are diagnosed with heart valve disease each year. TAVR is a procedure used for intermediate and higher open surgical-risk patients with severe narrowing of the aortic valve. In TAVR, a prosthetic valve is implanted percutaneously in the place of the diseased native valve. Patients who undergo TAVR are typically older with higher prohibitive risks and greater number of clinical comorbidities. Nearly 15-20 percent of patients who undergo TAVR — a less invasive procedure to replace the heart’s aortic valve — are readmitted within 30 days. Readmissions are costly to patient outcomes and are also associated with more than $40 billion in hospital costs annually.

The study analyzed patients in the Nationwide Readmissions Database (NRD) who underwent TAVR from January 2013 to September 2015. Complex survey methods, hierarchical regression and the ‘rms’ library were implemented to create a prediction ruler to determine probability for 30-day readmission. The study’s researchers performed an internal calibration with bootstrapping.

During the study period, a total of 39,305 patients underwent endovascular TAVR, and 6,380 (16.2 percent) were readmitted within 30 days. The final risk tool included the following variables:

  • Chronic kidney disease;
  • End-stage renal disease on dialysis;
  • Anemia;
  • Chronic lung disease;
  • Chronic liver disease;
  • Atrial fibrillation;
  • Length of stay >5 days;
  • Acute kidney injury; and
  • Discharge disposition.

The c-statistic of the model was 0.63. A score of 212 was associated with a more than 30 percent readmission rate.

“The creation of this tool and the results of the study are very assuring because it allows for better understanding how patients should be managed peri-TAVR. By recognizing patients at higher risk of readmission, we can guide post-discharge care coordination and improve transitions of care to decrease readmission, improve quality of life, reduce healthcare costs and ultimately impact mortality rates,” said lead author Sahil Khera, M.D., Massachusetts General Hospital.

“Use of the simple risk tool will allow the entire care team to quantify readmission risk and enhance our ability to provide personalized transitional care to hopefully mitigate this risk,” said co-author Sammy Elmariah, M.D., also from the Massachusetts General Hospital.

The authors are looking to start using this tool and incorporating into EMRs in hospital systems across the country in the near future.

Complete listing of SCAI 2018 late-breaking trials with links to articles.

 

Related TAVR Content

Recent Advances in Transcatheter Valve Technology

VIDEO: Outcomes Following Urgent TAVR - Results from the TVT Registry

VIDEO: TAVR for Degenerated Surgical Valves — Valve-in-Valve TAVR Procedures

 

Related Content

News | Cardiovascular Clinical Studies

June 24, 2021 — Data captured in American College of Cardiology (ACC) National Cardiovascular Data Registry (NCDR) ...

Home June 24, 2021
Home
News | Cardiovascular Clinical Studies

January 27, 2021 — A New York Institute of Technology research team has secured a five-year $1.8 million grant from the ...

Home January 27, 2021
Home
News | Cardiovascular Clinical Studies

July 22, 2020 — Eating chocolate at least once a week is linked with a reduced risk of heart disease, according to ...

Home July 22, 2020
Home
News | Cardiovascular Clinical Studies

July 1, 2020 — Carag AG announced receiving U.S. Food and Drug Administration (FDA) Investigational Device Exemption ...

Home July 01, 2020
Home
News | Cardiovascular Clinical Studies

January 20, 2020 — Scientists at Los Alamos and international partners have created the first 3-D images of a special ...

Home January 20, 2020
Home
News | Cardiovascular Clinical Studies

Environmental and lifestyle issues were popular this year, with pick up from both European Society of Cardiology (ESC) ...

Home December 23, 2019
Home
News | Cardiovascular Clinical Studies

November 26, 2019 — The University of Connecticut (UConn) Department of Kinesiology and Hartford Healthcare have ...

Home November 26, 2019
Home
News | Cardiovascular Clinical Studies

July 10, 2019 — The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During ...

Home July 10, 2019
Home
News | Cardiovascular Clinical Studies

July 3, 2019 — The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to ...

Home July 03, 2019
Home
News | Cardiovascular Clinical Studies

November 19, 2018 — The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent ...

Home November 19, 2018
Home
Subscribe Now